BRAF抑制剂联合抗EGFR单抗和伊立替康解救治疗BRAF V600E突变的转移性结肠癌一例报告并文献复习  

A case report of BRAF inhibitor combined with anti-EGFR monoclonal antibody and irinotecan in the treatment of metastatic colon cancer with BRAF V600E mutation and literature review

作　　者：彭黎明 王静 杨林 Peng Liming;Wang Jing;Yang Lin(Department of Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Oncology,Sanhuan Cancer Hospital,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科,北京市100021 [2]北京市朝阳区三环肿瘤医院肿瘤科,100021

出　　处：《中华结直肠疾病电子杂志》2020年第3期305-309,共5页Chinese Journal of Colorectal Diseases(Electronic Edition)

摘　　要：BRAF基因是RAF激酶家族的一员,约14%的原发性结直肠癌和8%转移性结直肠癌(mCRC)患者发生BRAF突变。BRAF V600E,作为BRAF突变mCRC最常见的类型,常规治疗效果差,疾病进展快、生存期短、预后差。中国医学科学院肿瘤医院收治一例BRAF V600E突变晚期结肠癌患者,二线化疗+靶向治疗肿瘤均无明显缩小,三线BRAF抑制剂联合化疗及靶向治疗取得部分缓解(PR),现报告如下。The BRAF gene is a member of the RAF kinase family,and BRAF mutations occur in approximately 14%of patients with primary CRC and 8%mCRC.BRAF V600E CRC,as the most common type of BRAF mutation mCRC,has poor conventional treatment efficacy,rapid disease progression,short survival,and poor prognosis.In Cancer Hospital,Chinese Academy of Medical Sciences,we received an advanced colon cancer patient with BRAF V600E mutation.Two-line therapy with chemotherapy and targeted therapy showed no significant tumor reduction.The third-line therapy,BRAF inhibitor combined with chemotherapy and targeted therapy,achieved PR(partial response).The report is as follows.

关 键 词：结肠肿瘤 突变 BRAF突变 BRAF抑制剂 肿瘤转移 

分 类 号：R735.35[医药卫生—肿瘤]